NCT04452214 2023-07-14
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
Phase 1 Completed
Cantargia AB
Memorial Sloan Kettering Cancer Center
Innovent Biologics (Suzhou) Co. Ltd.
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute